Efficacy and safety of thiopurinic immunomodulators (azathioprine and mercaptopurine) in steroid-dependent ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue 2, 2004, Pages 161-166

  Lopez Sanroman, A ^a   Bermejo, F ^a   Carrera, E ^a   Garcia Plaza, A ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; GLUCOCORTICOID; IMMUNOMODULATING AGENT; MERCAPTOPURINE; STEROID;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; BONE MARROW TOXICITY; CLINICAL ARTICLE; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ENDOCARDITIS; EPIGASTRIC PAIN; FEMALE; HERPES; HUMAN; LIVER TOXICITY; MALE; MEAN CORPUSCULAR VOLUME; NAUSEA; NEUTROPENIA; PANCREATITIS; PRIORITY JOURNAL; THROMBOCYTOPENIA; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; ADULT; AZATHIOPRINE; COLITIS, ULCERATIVE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 3242885920     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02030.x     Document Type: Article

References (36)

1. Faubion WA, Loftus EV, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255-60.
2. Nielsen OH, Vainer B, Rask-Madsen J. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther 2001; 15: 1699-708.
3. Menor C, Fueyo JA, Escribano O, et al. Determination of thiopurine methyltransferase activity in human erythrocytes by high-performance liquid chromatography. Comparison with the radiochemical method. Ther Drug Monit 2001; 23: 536-41.
4. Bermejo F, López San Román AL, Hinojosa J, Castro L, Jurado C, Gómez-Belda AB. Infliximab induces clinical, endoscopical and histological response in refractory ulcerative colitis. Rev Esp Enferm Dig 2004; 96: 94-101.
5. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J 1974; 4: 627-30.
6. Caprilli R, Carratu' R, Babbini M. A double-blind comparison of the effectiveness of azathioprine and sulfasalazine in idiopatic proctocolitis. Dig Dis 1975; 20: 115-20.
7. Rosenberg JL, Wall AJ, Levin B, Binder HJ, Kirsner JB. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 1975; 69: 96-9.
8. Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J 1982; 284: 1291-2.
9. Present DH, Chapman ML, Rubin PH. Efficacy of 6-mercaptopurine (6-MP) in refractory ulcerative colitis. Gastroenterology 1988; 94: A359.
10. Steinhart AH, Baker JP, Brzezinski A, Prokipchuk EJ. Azathioprine therapy in chronic ulcerative colitis. J Clin Gastroenterol 1990; 12: 271-5.
11. Lobo AJ, Foster PN, Burke DA, Johnston D, Axon ATR. The role of azathioprine in the management of ulcerative colitis. Dis Colon Rectum 1990; 33: 374-7.
12. Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 1990; 85: 717-22.
13. Bianchi Porro G, Petrillo M, Ardizzone S, Desideri S. Azathioprine in the treatment of ulcerative colitis. J Clin Gastroenterol 1991; 13: 113-4.
14. Hawthorne AB, Logan RFA, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992; 305: 20-2.
15. George J, Present DH, Pou R, Bodian C, Rubin PH. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996; 91: 1711-4.
16. Ardizzone S, Molteni F, Imbesi V, Bollani S, Bianchi Porro G. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol 1997; 25: 330-3.
17. Mate-Jimenez J, Hermida C, Cantero-Perona J, Moreno-Otero R. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000; 12: 1227-33.
18. Khan ZH, Mayberry JF, Spiers N, Wicks AC. Retrospective case series analysis of patients with inflammatory bowel disease on azathioprine. A district general hospital experience. Digestion 2000; 62: 249-54.
19. Kull E, Beau P. Efficacité comparée de l'azathioprine dans la rectolite hémorragique et dans la maladie de Crohn. Gastroenterol Clin Biol 2001; 25: 367-71.
20. Sood A, Midha V, Sood N, Avasthi G. Azathioprine versus sulfasalazine in maintenance of remission in severe ulcerative colitis. Indian J Gastroenterol 2003; 22: 79-81.
21. Paoluzi OA, Pica R, Marcheggiano A, et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment Pharmacol Ther 2002; 16: 1751-9.
22. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 485-9.
23. Pearson DC, May GR, Fick CK, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Int Med 1995; 122: 132-42.
24. 4 Binderow SR, Wexner SD. Current surgical therapy for mucosal ulcerative colitis. Dis Colon Rectum 1994; 37: 610-24.
25. Present DG, Meltzer SJ, Krumholz MP, Wolke A, Korelitz B. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111: 641-9.
26. Singleton JW, Law DH, Kelley ML, Mekhjian HS, Sturdevant RA. National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology 1979; 77: 870-82.
27. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025-30.
28. Evans WE, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001; 19: 2293-301.
29. Gisbert JP, Luna M, Mate J, Gonzalez-Guijarro L, Cara C, Pajares JM. Thiopurine methyltransferase activity and myelosuppression in inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Med Clin (Barc) 2003; 121: 1-5.
30. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol 1995; 131: 193-7.
31. Bowen DG, Selby WS. Use of 6-mercaptopurine in patients with inflammatory bowel disease previously intolerant of azathioprine. Dig Dis Sci 2000; 454: 1810-3.
32. Boulton-Jones JR, Pritchard K, Mahmoud AA. The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. Aliment Pharmacol Ther 2000; 14: 1561-5.
33. McGovern DPB, Travis SPL, Duley J, Shobowale-Bakre EIM, Dalton UR. Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity. Gastroenterology 2002; 122: 838-9.
34. Decaux G, Prospert F, Horsmans Y, Desager JP. Relationship between red cell mean corpuscular volume and 6-thioguanine nucleotides in patients treated with azathioprine. J Lab Clin Med 2000; 135: 256-62.
35. Thomas CW Jr, Lowry PW, Franklin CL, et al. Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Inflamm Bowel Dis 2003; 9: 237-45.
36. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001; 48: 642-6.